Skip to content

Dr. Andy May

Entre­pre­neur In Residence, DCVC Bio

Andy is an Entre­pre­neur In Residence at DCVC Bio. Andy has spent much of his career at early-stage biotech­nology companies, building teams and developing tech­nolo­gies from concept to commercial product. He currently works with a number of companies with technology platforms that are targeted towards solving some of the outstanding problems in gene and cell therapy. He was most recently the Chief Technology Officer at Sana Biotech­nology, where he led teams focused on targeted cellular delivery, genome engineering, compu­ta­tional biology and genomics. Prior to Sana, Andy was one of the first scientific leaders at the CZ Biohub, where he built a Genome Engineering platform, focusing on the design and engineering of cells and biological devices as diagnostics and ther­a­peu­tics, DNA repair mechanisms in genome editing, and large-scale single-cell sequencing experiments. Andy was also the Chief Scientific Officer at Caribou Biosciences. He was a co-founder and served on the Board of Directors at Intellia Ther­a­peu­tics. Earlier in his career, Andy developed commercial products for single-cell sequencing, cell-free DNA sequencing, HLA-typing and structural proteomics at Fluidigm Corporation, and worked in drug discovery teams at Thios Phar­ma­ceu­ti­cals and Signature Biosciences.

Andy was a Wellcome Trust Inter­na­tional Post­doc­toral Fellow in the Department of Structural Biology at Stanford University, having received his D.Phil. in Molecular Biophysics and a B.A. in Chemistry at the University of Oxford. He has published widely in leading scientific journals, and is an inventor on over 100 patents and patent applications.